EXTERNAL REPORT OF THE IDMC FOR SIOPEL 6

Date: 20 August 2013
Venue: WebEx conference
Attendees: Deborah Ashby
           Maarten Egeler
           Stefan Bielack

1 The IDMC has received the third interim report dated July 2013, on the first 60 patients treated in SIOPEL 6 and has read the report, which is deemed comprehensive and complete.

2 The report explains that this is a planned interim report focusing mainly on the efficacy of the cisplatin monotherapy +/- STS.

RECOMMENDATIONS TO THE STEERING GROUP

1 The IDMC concludes that the current efficacy results of chemotherapy do not raise any concerns as to a potential impairment of the efficacy of cisplatin through the addition of STS.

2 The IDMC recommends the continuation of the trial according to protocol